Key result
A nomogram combining MACK-3, platelets, and metabolic syndrome improves fibrotic NASH diagnostic accuracy to AUROC 0.81.
Why the study?
There is an immediate need for non-invasive accurate tests for diagnosing liver fibrosis in patients with non-alcoholic steatohepatitis (NASH).
Does a novel nomogram combining MACK-3, platelet count, and MetS accurately diagnose fibrotic NASH in adults with biopsy-proven NAFLD?
Cohort (n=636)
Yes
Does a novel nomogram combining MACK-3, platelet count, and MetS accurately diagnose fibrotic NASH in adults with biopsy-proven NAFLD?
A novel nomogram combining MACK-3, platelet count, and metabolic syndrome accurately identifies fibrotic NASH and, when combined with transient elastography, may reduce the need for liver biopsies.
Answers are grounded in this paper and cite their sources.
Nomogram outperformed MACK-3 for fibrotic NASH; leaves open prospective validation before changing biopsy thresholds.
BACKGROUND AND AIM: There is an immediate need for non-invasive accurate tests for diagnosing liver fibrosis in patients with non-alcoholic steatohepatitis (NASH). Previously, it has been suggested that MACK-3 (a formula that combines homeostasis model assessment-insulin resistance with serum serum aspartate aminotransferase and cytokeratin [CK]18-M30 levels) accurately identifies patients with fibrotic NASH. Our aim was to assess the performance of MACK-3 and develop a novel, non-invasive algorithm for diagnosing fibrotic NASH. METHODS: Six hundred and thirty-six adults with biopsy-proven non-alcoholic fatty liver disease (NAFLD) from two independent Asian cohorts were enrolled in our study. Liver stiffness measurement (LSM) was assessed by vibration-controlled transient elastography (Fibroscan). Fibrotic NASH was defined as NASH with a NAFLD activity score (NAS) ≥ 4 and F ≥ 2 fibrosis. RESULTS: Metabolic syndrome (MetS), platelet count and MACK-3 were independent predictors of fibrotic NASH. On the basis of their regression coefficients, we developed a novel nomogram showing a good discriminatory ability (area under receiver operating characteristic curve [AUROC]: 0.79, 95% confidence interval [CI 0.75-0.83]) and a high negative predictive value (NPV: 94.7%) to rule out fibrotic NASH. In the validation set, this nomogram had a higher AUROC (0.81, 95%CI 0.74-0.87) than that of MACK-3 (AUROC: 0.75, 95%CI 0.68-0.82; P < 0.05) with a NPV of 93.2%. The sequential combination of this nomogram with LSM data avoided the need for liver biopsy in 56.9% of patients. CONCLUSIONS: Our novel nomogram (combining MACK-3, platelet count and MetS) shows promising utility for diagnosing fibrotic NASH. The sequential combination of this nomogram and vibration-controlled transient elastography limits indeterminate results and reduces the number of unnecessary liver biopsies.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2020) conducted a cohort in Non-alcoholic fatty liver disease (NAFLD) (n=636). Novel nomogram (combining MACK-3, platelet count, and metabolic syndrome) vs. MACK-3 alone was evaluated on Diagnosis of fibrotic NASH (AUROC 0.81, 95% CI 0.74-0.87, p=< 0.05). A novel nomogram combining MACK-3, platelet count, and metabolic syndrome showed higher accuracy for diagnosing fibrotic NASH than MACK-3 alone.
Synapse has enriched 10 related papers. Consider them for comparative context: